Polycythemia vera is associated with an elevated risk of both arterial (e.g., myocardial infarction) and venous thrombotic events, driven by increased hematocrit, elevated blood viscosity, abnormal platelet activation, and JAK2 mutation-mediated inflammation. This evidence concerns the gene JAK2 and acquired polycythemia vera.